Scott M. Wasserman - 19 Oct 2026 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
21 Oct 2026, 16:10:04 UTC
Prior SEC filing
16 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David McIntyre, attorney-in-fact
Filing notes and source

Key filing fact

Scott M. Wasserman filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 21 Oct 2026.

Key facts

  • This page summarizes Scott M. Wasserman's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 21 Oct 2026, 16:10.

Change

  • Previous filing in this sequence was filed on 16 Apr 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002118767 Primary reporting owner

Wasserman Scott M.

Relationship
Director
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Signature
/s/ David McIntyre, attorney-in-fact
Signature date
21 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+310,000
Change %
Price
$0.000000*
Shares after
310,000
Date
19 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
310,000
Exercise price
$1.64
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options will vest and become exercisable in equal annual installments over three years commencing from October 19, 2026, subject to the Reporting Person's continued service through each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .